Month: November 2015

About Dupixent Dupixent is currently approved in the EU for patients 12 years and older as an add on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) steroids, who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product […]

Read more

Results: Total patients who were screened were 343, and among them 56 (16.32%) had stopped their medication. The commonest cause for discontinuation was inability to afford medication. Conclusion: Steady supply of medication to patients can improve the outcome of their illness.. steroids For severe eye allergy symptoms that have been going on a while, Corticosteroid […]

Read more

In particularly acute or severe cases, doctors sometimes also prescribe corticosteroids to address heart, blood steroids, and other life threatening problems that AOSD can cause. Anti TNF therapy steroids, aimed at a component of the immune system, may be a promising treatment. There is a new class of drugs called biologics that are very promising […]

Read more